Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Smith & Nephew Snats ( (SNN) ) has shared an announcement.
Smith & Nephew plc, a company involved in the healthcare industry, announced on September 1, 2025, that its total issued share capital as of August 31, 2025, consists of 877,718,356 ordinary shares, with 6,748,465 held in treasury. This results in a total of 870,969,891 voting shares, which shareholders should use as a reference for notifying changes in their interest under FCA rules.
The most recent analyst rating on (SNN) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
Smith & Nephew Snats’ strong financial performance and positive earnings call are the most significant factors driving the score. The stock’s bullish technical indicators are tempered by overbought signals, and the valuation suggests it may be overvalued. Despite challenges in emerging markets and potential tariff impacts, the company’s strategic initiatives and share buyback plan reflect confidence in sustaining growth.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Average Trading Volume: 965,986
Technical Sentiment Signal: Buy
Current Market Cap: $16.3B
For a thorough assessment of SNN stock, go to TipRanks’ Stock Analysis page.